Neuropathix, Inc. is a pioneering biopharmaceutical company advancing globally patented, synthetic cannabinoid-inspired therapeutics for the treatment of neurodegenerative and neuropathic diseases. Headquartered at the Pennsylvania Biotechnology Center with its wholly owned subsidiary Kannalife Sciences, Inc., it’s lead drug candidate, KLS-13019, targets key drivers of neuroinflammation and mitochondrial dysfunction, including mNCX-1, GPR55, and the NLRP3 inflammasome. The company’s innovation has been recognized through substantial non-dilutive funding, including a $1.5 million grant from The Michael J. Fox Foundation for Parkinson’s Research and $3.3 million from the NIH HEAL Initiative to support IND-enabling studies to advance KLS-13019 toward clinical trials.
Company Details
- Employees
- 3
- Address
- 3805 Old Easton Road, Doylestown,pa 18902,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.neuropathix.com
- Keywords
- jobs.
- HQ
- Doylestown, PA
Neuropathix, Inc. Questions
Neuropathix, Inc.'s website is http://www.neuropathix.com
Neuropathix, Inc.'s LinkedIn profile is https://www.linkedin.com/company/neuropathix
Neuropathix, Inc. has
3 employees.
View email and phone details for 3
employees at Neuropathix, Inc..
Neuropathix, Inc.'s industry is
Pharmaceutical Manufacturing
Neuropathix, Inc.'s top competitors are
Biscayne Neurotherapeutics Inc,
Neuraltus Pharmaceuticals,
Aestus Partners Llc,
Kannalife Sciences, Inc.,
Cellectar Biosciences, Inc.,
Artelo Biosciences, Inc.,
Kannalife, Inc.,
Guardian Therapeutics Inc,
Swanbio Therapeutics,
Neurotherapia, Inc..
Neuropathix, Inc.'s categories are Pharmaceutical Manufacturing
